---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-089856"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:29:48.529871+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026

## Summary
- Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).
- Total net revenue Q4 $0.6M vs $11.6M, mainly from YUTIQ deferred revenue recognition.
- Cash, cash equivalents & investments $306M as of Dec 31, 2025; provides runway into Q4 2027.
- Both Phase 3 wet AMD trials (LUGANO, LUCIA) on track; topline data expected mid-2026. DME trials dosed.
- Appointed Michael Campbell as Chief Commercial Officer for DURAVYU launch readiness.

## SEC filing metadata
- accession: 0001193125-26-089856
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526089856/0001193125-26-089856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526089856/eypt-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-089856
- JSON: https://secwatch.observer/filing/0001193125-26-089856.json
- Plain text: https://secwatch.observer/filing/0001193125-26-089856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.